Tolerance of benznidazole in a United States Chagas Disease clinic

David A Miller; Salvador Hernandez; Lissette Rodriguez De Armas; Samantha J Eells; Mahmoud M Traina; Loren G Miller; Sheba K Meymandi

doi:10.1093/cid/civ005

Tolerance of benznidazole in a United States Chagas Disease clinic

Clin Infect Dis. 2015 Apr 15;60(8):1237-40. doi: 10.1093/cid/civ005. Epub 2015 Jan 18.

Authors

David A Miller¹, Salvador Hernandez², Lissette Rodriguez De Armas², Samantha J Eells¹, Mahmoud M Traina², Loren G Miller¹, Sheba K Meymandi²

Affiliations

¹ Los Angeles Biomedical Research Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance.
² Center of Excellence for Chagas Disease, Olive View-UCLA Medical Center, Sylmar, California.

PMID: 25601454
DOI: 10.1093/cid/civ005

Abstract

The US-based Center of Excellence for Chagas Disease performed an observational study on the safety and tolerance of benznidazole 5 mg/kg/day for 60 days in 30 adults with chronic Chagas disease. The side-effect profile was suboptimal, including 5 cases of debilitating neuropathy and an unusually high angioedema rate.

Keywords: Chagas disease; United States; benznidazole; drug tolerance; trypanosomiasis.

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Angioedema / chemically induced
Angioedema / epidemiology
Chagas Disease / drug therapy*
Drug-Related Side Effects and Adverse Reactions / epidemiology*
Female
Humans
Male
Middle Aged
Nitroimidazoles / adverse effects*
Nitroimidazoles / therapeutic use
Peripheral Nervous System Diseases / chemically induced
Peripheral Nervous System Diseases / epidemiology
Retrospective Studies
Trypanocidal Agents / adverse effects*
Trypanocidal Agents / therapeutic use
United States
Young Adult

Substances

Nitroimidazoles
Trypanocidal Agents
benzonidazole